2018
Transcatheter Aortic Valve Replacement versus Medical Management among Patients with Aortic Stenosis and Left Ventricular Systolic Dysfunction
Lowenstern A, Vora A, Dunning A, Schulte P, Vemulapalli S, Hughes G, Velazquez E, Harrison J, Samad Z. Transcatheter Aortic Valve Replacement versus Medical Management among Patients with Aortic Stenosis and Left Ventricular Systolic Dysfunction. Structural Heart 2018, 2: 388-395. DOI: 10.1080/24748706.2018.1500049.Peer-Reviewed Original ResearchTranscatheter aortic valve replacementCoronary artery bypass graftSevere aortic stenosisVentricular systolic dysfunctionAortic valve replacementAortic stenosisMedical managementSystolic dysfunctionValve replacementOutcomes of patientsArtery bypass graftVentricular ejection fractionIschemic heart diseaseCause mortalityMultivariable adjustmentRenal insufficiencyTAVR patientsTransthoracic echocardiogramEjection fractionHeart failureMedian ageBypass graftHistorical cohortTherapeutic optionsPatient population
2013
Influence of Crossover on Mortality in a Randomized Study of Revascularization in Patients With Systolic Heart Failure and Coronary Artery Disease
Doenst T, Cleland JG, Rouleau JL, She L, Wos S, Ohman EM, Krzeminska-Pakula M, Airan B, Jones RH, Siepe M, Sopko G, Velazquez EJ, Racine N, Gullestad L, Filgueira JL, Lee KL. Influence of Crossover on Mortality in a Randomized Study of Revascularization in Patients With Systolic Heart Failure and Coronary Artery Disease. Circulation Heart Failure 2013, 6: 443-450. PMID: 23515275, PMCID: PMC3721746, DOI: 10.1161/circheartfailure.112.000130.Peer-Reviewed Original ResearchConceptsHeart failureCoronary artery bypass graft surgeryIschemic Heart Failure (STICH) trialPatient/family decisionArtery bypass graft surgeryImpact of CABGBypass graft surgeryHeart Failure TrialMultivariable Cox modelSystolic heart failureCoronary artery diseaseIschemic heart diseaseAcute decompensationGraft surgeryProgressive symptomsArtery diseaseMedical therapySurgical treatmentFailure TrialPatient populationHeart diseaseCABGCommon reasonCox modelPatients
2012
A Quality Improvement Framework for Equity in Cardiovascular Care: Results of a National Collaborative
Siegel B, Sears V, Bretsch JK, Wilson M, Jones KC, Mead H, Hasnain-Wynia R, Ayala RK, Bhalla R, Cornue CM, Emrich CM, Patel P, Setzer JR, Suitonu J, Velazquez EJ, Eagle KA, Winniford MD. A Quality Improvement Framework for Equity in Cardiovascular Care: Results of a National Collaborative. Journal For Healthcare Quality 2012, 34: 32-43. PMID: 23552200, DOI: 10.1111/j.1945-1474.2011.00196.x.Peer-Reviewed Original ResearchConceptsPatient demographic dataCardiovascular careDemographic dataHeart Failure QualityPatient demographic characteristicsMinority patient populationAcute myocardial infarctionCare of minoritiesEvidence-based practice toolsStandardized collectionEvidence-based measuresComposite measureHispanic patientsAbility of hospitalsMyocardial infarctionPatient populationPatient raceQuality improvement toolsCardiac careMAIN OUTCOMEQuality improvement frameworkCardiac volumesQuality improvement methodsHospitalEthnic disparities
2010
Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial
Nilsson KR, Al-Khatib SM, Zhou Y, Pieper K, White HD, Maggioni AP, Kober L, Granger CB, Lewis EF, McMurray JJ, Califf RM, Velazquez EJ. Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart 2010, 96: 838. PMID: 20406769, DOI: 10.1136/hrt.2009.180182.Peer-Reviewed Original ResearchConceptsRhythm control strategyAcute Myocardial Infarction trialMyocardial Infarction trialAtrial fibrillationMyocardial infarctionRate control strategyEarly mortalityAnti-arrhythmic drug therapyTreatment of AFPeri-infarct periodIncidence of strokeManagement of patientsRisk of deathLate mortalityPatient populationDrug therapyCox modelPatientsMortalityInfarctionStrokeValsartanTrialsDeathDaysEvidence for the efficacy of ARBs across the cardiovascular continuum
Gupta M, Honos GN, Velazquez EJ, Chung N, Oigman W, Maggioni AP. Evidence for the efficacy of ARBs across the cardiovascular continuum. Current Medical Research And Opinion 2010, 26: 1203-1218. PMID: 20302552, DOI: 10.1185/03007991003712159.Peer-Reviewed Original ResearchConceptsAngiotensin II receptor blockersPatient populationARB classCV continuumPre-specified risk factorsMajor CV outcomesII receptor blockersPrimary prevention studiesCardiovascular disease riskAdditional patient populationsDifferent patient populationsNumerous patient populationsMajor literature databasesCardiovascular continuumCV eventsCV morbidityCV outcomesReceptor blockersSecondary preventionACE inhibitorsAntihypertensive agentsOngoing trialsPrevention StudyRisk factorsDisease risk
2005
Therapies to prevent heart failure post-myocardial infarction
Thomas KL, Velazquez EJ. Therapies to prevent heart failure post-myocardial infarction. Current Heart Failure Reports 2005, 2: 174-182. PMID: 16332310, DOI: 10.1007/bf02696647.Peer-Reviewed Original ResearchConceptsPost-MI heart failureHeart failureMyocardial infarctionPresence of HFHeart failure post-myocardial infarctionEvidence-based medicationsMortality of patientsOutcomes of patientsVentricular systolic dysfunctionLower blood pressureTreatment of patientsAcute myocardial infarctionPost-myocardial infarctionKillip classSystolic dysfunctionCommon complicationBlood pressureClinical factorsRevascularization proceduresInfarct sizePoor prognosisPatient populationMale genderPost-MIRisk factors